Chen et al., 2023 - Google Patents
Evaluative effectiveness of follicular output rate, ovarian sensitivity index, and ovarian response prediction index for the ovarian reserve and response of low …Chen et al., 2023
- Document ID
- 665177036240162642
- Author
- Chen Z
- Li W
- Ma S
- Li Y
- Lv L
- Huang K
- Gong A
- Publication year
- Publication venue
- Zygote
External Links
Snippet
The aim was to explore the implications of follicular output rate (FORT), ovarian sensitivity index (OSI), ovarian response prediction index (ORPI), and follicle-to-oocyte index (FOI) in low-prognosis patients defined by POSEIDON criteria. In total, 4030 fresh in vitro fertilization …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sharma et al. | Factors influencing the cumulative conception rate and discontinuation of in vitro fertilization treatment for infertility | |
Esinler et al. | Impact of isolated obesity on ICSI outcome | |
Purcell et al. | Asian ethnicity is associated with reduced pregnancy outcomes after assisted reproductive technology | |
Qiu et al. | Effect of body mass index on pregnancy outcomes with the freeze-all strategy in women with polycystic ovarian syndrome | |
Hu et al. | Perinatal outcome in young patients with diminished ovarian reserve undergoing assisted reproductive technology | |
McAvey et al. | How many eggs are needed to produce an assisted reproductive technology baby: is more always better? | |
Aflatoonian et al. | Fresh versus frozen embryo transfer after gonadotropin-releasing hormone agonist trigger in gonadotropin-releasing hormone antagonist cycles among high responder women: a randomized, multi-center study | |
Xi et al. | Comparison between PPOS and GnRHa-long protocol in clinical outcome with the first IVF/ICSI cycle: a randomized clinical trial | |
Keane et al. | Higher β-HCG concentrations and higher birthweights ensue from single vitrified embryo transfers | |
Huang et al. | Timing of frozen-thawed embryo transfer after controlled ovarian stimulation in a non-elective freeze-all policy | |
Benmachiche et al. | Impact of mid-luteal phase GnRH agonist administration on reproductive outcomes in GnRH agonist-triggered cycles: a randomized controlled trial | |
Seow et al. | Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: a randomized controlled trial | |
Song et al. | Administration effects of single‑dose GnRH agonist for luteal support in females undertaking IVF/ICSI cycles: A meta‑analysis of randomized controlled trials | |
Pelinck et al. | Perinatal outcome in singletons after modified natural cycle IVF and standard IVF with ovarian stimulation | |
Huang et al. | Decreased endometrial thickness is associated with higher risk of neonatal complications in women with polycystic ovary syndrome | |
Su et al. | Age is a major prognosticator in extremely low oocyte retrieval cycles | |
Qiu et al. | The influence of polycystic ovarian syndrome on obstetric and neonatal outcomes after frozen-thawed embryo transfer | |
Pelinck et al. | Is the birthweight of singletons born after IVF reduced by ovarian stimulation or by IVF laboratory procedures? | |
Coskun et al. | The role of anti-Mullerian hormone in predicting the response to clomiphene citrate in unexplained infertility | |
Luo et al. | The role of serum vitamin D in patients with normal ovarian reserve undergoing the first IVF/ICSI cycle | |
Jin et al. | Live birth rates after natural cycle versus hormone replacement therapy for single euploid blastocyst transfers: a retrospective cohort study | |
Bortoletto et al. | Time from oocyte retrieval to frozen embryo transfer in the natural cycle does not impact reproductive or neonatal outcomes | |
Yılmaz et al. | Effect of the afterloaded external guidance embryo transfer technique on pregnancy rates in single embryo transfer cycles | |
Lin et al. | Progestin-primed ovarian stimulation with clomiphene citrate supplementation may be more feasible for young women with diminished ovarian reserve compared with standard progestin-primed ovarian stimulation: A retrospective study | |
Chen et al. | Evaluative effectiveness of follicular output rate, ovarian sensitivity index, and ovarian response prediction index for the ovarian reserve and response of low-prognosis patients according to the POSEIDON criteria: a retrospective study |